Results 201 to 210 of about 6,027,899 (340)

The Tunisian Pharmaceutical Sector in Transformation: Inventory of Fixtures and Innovation Prospects [PDF]

Since the entrance of Tunisia to the World Trade Organisation (WTO) in 1995, the Tunisian pharmaceutical industry has recorded considerable changes. Notably, with the extension of patentability to pharmaceuticals, the sector is now at a dynamic stage of ...
Nejla Yacoub
core  

Twenty years of inhaler therapy: A nationwide drug utilization study

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to map nationwide trends and prescribing patterns in inhaler use from 2004 to 2023. In light of evolving clinical guidelines and attention to the environmental impact of inhalers within recent years, we also examined variation in prescribing behaviour and patient‐level treatment choices. Methods Using nationwide health registries,
Katrine Bitsch Johansen, Lars Christian Lund, Zandra Nymand Ennis, Andrew Scourfield, Anders Løkke, Sidsel Arnspang Pedersen   +5 more
wiley   +1 more source

Overcoming Innovation Limits through Outward FDI: The Overseas Acquisition Strategy of Indian Pharmaceutical Firms [PDF]

A host of strategic government policies including a process patent regime led to the rise of Indian pharmaceutical firms with significant process development capabilities.
Pradhan, Jaya Prakash
core  

Clinical relevance of pharmacogenomic information for improving prescribing practices in acutely admitted older medical patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Safe prescribing and effective medication review during acute hospitalization depends on accurate information about liver and kidney function because these organs are responsible for the elimination of most medications. While estimates for kidney function are widely used, comparable markers of hepatic drug‐metabolizing capacity are not routinely ...
Louise Westberg Strejby Christensen, Anne Kirstine Boas, Emilie Clausen, Nicoline Elers Koch, Anne Byriel Walls, Lotte Stig Nørgaard, Michael Asger Andersen, Anissa Aharaz, Rikke Lundsgaard Nielsen, Olivia Bornæs, Juliette Tavenier, Baker Nawfal Jawad, Helle Gybel Juul‐Larsen, Esben Iversen, Ove Andersen, Lona Louring Christrup, Kim Peder Dalhoff, Morten Baltzer Houlind   +17 more
wiley   +1 more source

Patient‐reported outcomes and medication errors during oral antitumour therapy in paediatrics: Results from the youngAMBORA care programme

British Journal of Clinical Pharmacology, EarlyView.
Aim Increasing use of oral antitumour therapeutics (OAT) in paediatrics is associated with numerous advantages, but also with error‐prone aspects. Based on the randomized AMBORA trial including adults treated with various OAT, we developed a tailored pharmacological/pharmaceutical care programme for children and their caregivers during OAT treatment ...
Phyllis Lensker, Lisa Cuba, Frank Dörje, Martin F. Fromm, Markus Metzler   +4 more
wiley   +1 more source

Pharmaceutical Prices and Political Activity [PDF]

Drug prices have been a conspicuous political issue in much of recent history, but no more so than during health care reform debates in 1993 and 1994.
Catherine Wolfram, Sara Fisher Ellison
core  

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics

British Journal of Clinical Pharmacology, EarlyView.
Dyfrig A. Hughes, Henry Fong, Grace Hampson, Catrin O. Plumpton, Chris Sampson   +4 more
wiley   +1 more source

Economic evaluations of antiobesity medications: A systematic literature review

British Journal of Clinical Pharmacology, EarlyView.
The global prevalence of obesity is rising rapidly. With several antiobesity medications approved and many more in development, understanding their economic value is increasingly important. This study reviews full economic evaluations of approved antiobesity medications to assess cost‐effectiveness and inform reimbursement and access decisions.
Martina Jurković, Almir Fajkić, Andrea Katrin Faour, Mirna Momčilović, Petra Turčić, Andrej Belančić   +5 more
wiley   +1 more source

RETRACTED ARTICLE: Learnings from Industry 4.0 for transitioning towards Industry 4.0+: challenges and solutions for Indian pharmaceutical sector. [PDF]

Ann Oper Res
Sharma M, Sehrawat R, Giannakis M, Dwivedi YK.   +3 more
europepmc   +1 more source

Explaining Pharmaceutical R&D Growth Rates at the Industry Level: New Perspectives and Insights [PDF]

This paper uses aggregate data for the major pharmaceutical companies in the U.S. to study the rate of growth in pharmaceutical R&D intensity over the period from 1952 to 2001.
Santerre, Rexford, Vernon, John, Giaccotto, Carmelo   +2 more
core